10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

FORM 10Q

_________________

(Mark One)

[X]QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

[  ]TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from __________ to ___________

Commission file number: 333-174853

GLOBAL GREEN, INC.

(Exact name of registrant as specified in its charter)

Florida	20-1515998
(State of Incorporation)	(IRS Employer ID Number

2820 Remington Green Circle, Tallahassee, Florida 32308

(Address of principal executive offices)

(850) 597-7906

(Registrant's Telephone number)

 (Former Address and phone of principal executive offices)

Indicate by check mark  whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the  past 12 months (or for such  shorter  period that the  registrant  was required  to file  such  reports),  and  (2)  has  been  subject  to the  filing requirements for the past 90 days.   Yes [X]  No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 for Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes [X]  No [  ]

Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[    ]	Accelerated filer	[    ]
Non-accelerated filer	[    ]	Smaller reporting company	[ X ]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes [  ]No [X]

Indicate the number of share outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of  November 10, 2014, there were 745,761,432 shares of the registrant's common stock issued and outstanding.

2

PART I – FINANCIAL INFORMATION			Page
Item 1.  Financial Statements(Unaudited)			4
	Balance Sheets – September 30, 2014 and December 31, 2013 (Audited)		4
	Statements of Operations  -
		Three and nine months ended September 30, 2014 and 2013 and From Inception (July 12, 2004) to September 30, 2014	5
	Statements of Changes in Shareholders' Deficit –
		From Inception (July 12, 2004) to September 30, 2014	6
	Statements of Cash Flows –
		Nine months ended September 30, 2014 and 2013 and From Inception (July 12, 2004) to September 30, 2014	7
	Notes to the Financial Statements		8
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations			14
Item 3.  Quantitative and Qualitative Disclosures About Market Risk – Not Applicable			17
Item 4. Controls and Procedures			17
PART II – OTHER INFORMATION
Item 1.  Legal Proceedings –Not Applicable			18
Item 1A.  Risk Factors - Not Applicable			18
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds – Not Applicable			18
Item 3.  Defaults Upon Senior Securities – Not Applicable			18
Item 4.  Mine Safety Disclosure – Not Applicable			18
Item 5.  Other Information – Not Applicable			18
Item 6.  Exhibits			19
SIGNATURES			20

3

PART I

ITEM 1. FINANCIAL STATEMENTS

Global Green, Inc.

 (A Development Stage Company)

Consolidated Balance Sheets

September 30, 2014 and December 31, 2013

(unaudited)

	September 30, 2014			December 31, 2013
ASSETS
Current assets
Cash and cash equivalents	$	27,181		$	113,532
Travel advances to officer		2,000			6,000
Prepaid expenses		-			750
Total current assets		29,181			120,282
Intangible asset, net		5,543			5,795
Total assets	$	34,724		$	126,077
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	27,059		$	25,928
Due to shareholders		500			500
Convertible advance- related party (see Note 7)		195,000			235,000
Total liabilities		222,559			261,428
Shareholders' deficit:
Preferred stock; no par value; 100,000,000		-			-
shares authorized; no shares outstanding at
September 30, 2014 or December 31, 2013
Common stock; $.00001 par value; 3,000,000,000		7,458			7,458
shares authorized; 745,761,432 shares issued and
outstanding at September 30, 2014 or December 31, 2013
Additional paid in capital		285,573			285,573
Deficit accumulated during the development stage		(480,866	)		(428,382	)
Total shareholders' deficit		(187,835	)		(135,351	)
Total liabilities and shareholders' deficit	$	34,724		$	126,077

 See accompanying Notes to the Consolidated Financial Statements

4

Global Green, Inc.

 (A Development Stage Company)

Consolidated Statement of Operations

For the Nine and Three Months Ended September 30, 2014 and 2013

and the Period from Inception(July 12, 2004) to September 30, 2014

(unaudited)

	Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013			Three Months Ended September 30, 2014			Three Months Ended September 30, 2013			Inception to September 30, 2014
REVENUES	$	-		$	-		$	-		$	-		$	-
OPERATING EXPENSES
Professional fees		17,931			30,516			5,040			15,494			178,099
Testing for U.S. Department of     Agriculture's approval		-			-			-			-			137,800
General and administrative		10,013			48,533			1,940			20,873			84,612
Investor relations		9,000			-			3,000			-			32,231
Interest expense (see Note 7)		8,038			10,908			2,438			3,408			21,025
Consulting fees		-			-			-			-			10,200
Stock transfer agent fees		2,250			1,570			600			485			10,422
Vaccine testing		5,000			-			-			-			5,000
Amortization		252			252			84			84			1,288
Bank fees		-			51			-			-			189
Total operating expenses		52,484			91,830			13,102			40,344			480,866
NET LOSS	$	(52,484	)	$	(91,830	)	$	(13,102	)	$	(40,344	)	$	(480,866	)
Net loss per share applicable to    common stockholders — basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average number of    shares outstanding – basic and diluted		745,761,432			745,761,432			745,761,432			745,761,432

 See accompanying Notes to the Consolidated Financial Statements

5

Global Green, Inc.

(A Development Stage Company)

Consolidated Statement of Shareholders' Deficit

For the Period from Inception (July 12, 2004) to September 30, 2014

(unaudited)

								Accumulated
								During the			Total
	Common		Common		Additional			Development			Shareholders'
	Shares		Stock		Paid in Capital			Stage			Deficit
INCEPTION, July 12, 2004		-	$	-	$	-		$	-		$	-
Share issuance, September 2004		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2004		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2005		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2006		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2007		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2008		3,141,597		314		(314	)		-			-
BALANCE, December 31, 2009		3,141,597		314		(314	)		-			-
Recapitalization due to 10 to 1 stock split		28,274,370		-		-			-			-
Stock based compensation		20,000,000		200		-			-			200
Share issuance		683,097,847		6,831		-			-			6,831
Net loss		-		-		-			(5,728	)		(5,728	)
BALANCE, December 31, 2010		734,513,814		7,345		(314	)		(5,728	)		1,303
Share issuance		11,247,618		113		285,887			-			286,000
Net loss		-		-		-			(191,800	)		(191,800	)
BALANCE, December 31, 2011		745,761,432		7,458		285,573			(197,528	)		95,503
Net loss		-		-		-			(114,900	)		(114,900	)
BALANCE, December 31, 2012		745,761,432		7,458		285,573			(312,428	)		(19,397	)
Net loss		-		-		-			(115,954	)		(115,954	)
BALANCE, December 31, 2013		745,761,432		7,458		285,573			(428,382	)		(135,351	)
Net loss		-		-		-			(52,484	)		(52,484	)
BALANCE, September 30, 2014		745,761,432	$	7,458	$	285,573		$	(480,866	)	$	(187,835	)

See accompanying Notes to the Consolidated Financial Statements

6

Global Green, Inc.

 (A Development Stage Company)

Consolidated Statement of Cash Flows

For the Periods Ended September 30, 2014 and 2013

and the Period from Inception(July 12, 2004) to September 30, 2014

(unaudited)

	Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013			Inception to September 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(52,484	)	$	(91,830	)	$	(480,866	)
Adjustments to reconcile net loss to net cash
from operating activities:
Amortization		252			252			1,288
Stock based compensation		-			-			200
Change in assets and liabilities:
Travel advances to officer		4,000			-			(2,000	)
Prepaid expenses		750			375			-
Accounts payable and accrued expenses		1,131			(2,424	)		27,059
Due from shareholders		-			(2,000	)		-
Due to shareholders		-			-			500
Net cash from operating activities		(46,351	)		(95,627	)		(453,819	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from share issuance		-			-			286,000
Proceeds from convertible advance - related party		-			300,000			300,000
Repayments on convertible advance - related party		(40,000	)		(37,000	)		(105,000	)
Net cash from financing activities		(40,000	)		263,000			481,000
NET CHANGE IN CASH		(86,351	)		167,373			27,181
CASH, beginning of period		113,532			4,027			-
CASH, end of period	$	27,181		$	171,400		$	27,181
SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES:
Common stock issued for acquisition of
Global Green International, Inc.	$	-		$	-		$	6,831

See accompanying Notes to the Consolidated Financial Statements

7

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

NOTE 1 NATURE OF ORGANIZATION

Global Green, Inc. (the "Company") is a Florida Corporation incorporated on July 12, 2004 as a wholly owned subsidiary of Global Assets & Services, Inc.  In September 2004, the Company was spun out into a separate legal entity.  The Company changed its name from The Global Tech Assets, Inc. to Global Green, Inc. in April 2010 and its fiscal period end is December 31.

The Company is in the development stage.  The principal activities during the development stage include organizing the corporate structure, implementing the Company's business plan and raising capital.  Although the Company was formed in 2004, it did not have any operating activities until 2010.

Under the Share Exchange Agreement executed on November 29, 2010, between the Company and Nutritional Health Institute, LLC ("NHIL"), the Company acquired 100% of the issued and outstanding stock of Global Green International, Inc. ("GGII"), a wholly owned subsidiary of NHIL. At the same time, the Company issued approximately 683 million shares of its common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned acquisition as per the Share Exchange Agreement, the Company has become a majority-owned subsidiary of NHIL. As the effective control over GGII did not change, in accordance with Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") 805 Business Combinations, GGII is consolidated at its book value (See Note 4).  Prior to November 2010, GGII had no assets or operations, so there is no impact to the historical financial statements.

GGII, a wholly-owned subsidiary of the Company, has been granted the exclusive worldwide rights (the "Licensing Agreement") to manufacture, distribute, market and sell a Salmonella Antigen and Vaccine (the "Vaccine").  The Licensing Agreement was executed between NHIL and GGII before the Company acquired the 100% ownership of GGII and is the only asset of GGII.

In February 2011, the Vaccine has been entered into the final phase of becoming a United States Department of Agriculture ("USDA") approved vaccine for the in ovo vaccination of chicken eggs to provide immunity against Salmonella bacteria. In May 2011, the United States Patent and Trademark Office granted a patent for the method and composition in the Vaccine. In August 2011, an additional patent was granted related to the vaccine.

NOTE 2 GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.  As of September 30, 2014, the Company has incurred net losses of $480,866 since inception (July 12, 2004).

Management's plans include raising capital through the equity markets to fund operations and eventually, the generating of revenue through its business; however, there can be no assurance that the Company will be successful in such activities.  These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

8

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") on the accrual basis of accounting.  All significant intercompany accounts and transactions have been eliminated in consolidation.  The interim financial statements reflect all adjustments, which are, in the opinion of management, necessary in order to make the financial statements not misleading.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the financial statements.  The significant accounting policies, estimates and related judgments underlying the Company's financial statements are summarized below.  In applying these policies, management makes subjective judgments that frequently require estimates about matters that are inherently uncertain.

Cash and Cash Equivalents

The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents.  There were no cash equivalents at September 30, 2014 and December 31, 2013.

Revenue Recognition

The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2014.

Earnings Per Share

The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2014 and December 31, 2013.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash.

Occasionally, cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation ("FDIC").  Accordingly, the Company places its cash and cash equivalents with financial institutions considered by management to be of high credit quality.  At times, the Company's cash balances may be in excess of the FDIC limits.

9

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

Fair Value of Financial Instruments

The Company adopted Statement of Financial Accounting Standards ("SFAS") No. 157 Fair Value Measurements ("SFAS 157"), superseded by ASC 820-10, which defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. The impact of adopting ASC 820-10 was not significant to the Company's financial statements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.  Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.  The valuation of our derivative liability is determined using Level 1 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014 and December 31, 2013.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.  These financial instruments include cash, accounts payable, accrued expenses and advance.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.

10

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

The Company files income tax returns in the United States and Florida, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company's federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with FASB ASC 740, Income Taxes, and has not identified any significant tax positions, other than those disclosed.

Subsequent Events

In accordance with FASB ASC 855, Subsequent Events, the Company evaluated subsequent events through November 10, 2014, the date the financial statements were available for issue.

NOTE 4INTANGIBLE ASSET

The Company accounts for its intangible asset in accordance FASB ASC 350 Intangibles—Goodwill and Other.  The intangible assets consist of the Licensing Agreement and is carried at an allocated cost, less accumulated amortization.  The Licensing Agreement was executed on November 29, 2010 between NHIL and GGII, before the Company acquired the 100% ownership of GGII as described in Note 1. The provisions in the License Agreement include the Company's responsibilities to protect the Vaccine information and to assume financial responsibilities for the acquisition of USDA approval of the Vaccine.  The License Agreement has no expiration date, but is being amortized over the 20 year legal life of the related patent. As the effective control over GGII did not change after acquisition by the Company, in accordance with FASB ASC 805, Business Combinations, the License Agreement is consolidated at the book value.

Components of intangible assets at the periods ended are as follows:

	September 30, 2014			December 31, 2013
License agreement	$	6,831		$	6,831
Accumulated amortization		(1,288	)		(1,036	)
	$	5,543		$	5,795

11

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

NOTE 5TAXES

The components of income tax expense for the periods ended are as follows:

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Current tax benefit	$	(19,734	)	$	(34,528	)	$	(137,208	)
Change in valuation allowance		19,734			34,528			137,208
	$	-		$	-		$	-

The difference between income tax expense computed by applying the statutory federal income tax rate to earnings before taxes for the periods ended are as follows:

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Pretax loss at federal statutory rate	$	(17,845	)	$	(31,012	)	$	(124,072	)
State income benefit, net of federal benefit		(1,889	)		(3,284	)		(13,136	)
Change in valuation allowance		19,734			34,296			137,208
	$	-		$	-		$	-

The components of deferred taxes are as follows:

	September 30, 2014			December 31, 2013
Deferred income tax assets:
Operating loss carryforwards	$	137,208		$	161,073
Less: Valuation allowance		(137,208	)		(161,073	)
Net deferred tax asset	$	-		$	-

At September 30, 2014 and December 31, 2013, a valuation allowance was established for the entire amount of the net deferred tax asset as the realization of the deferred tax asset is dependent on future taxable income.

At September 30, 2014, the Company had net operating loss carryforwards for tax purposes of $480,866, which will expire beginning in 2031, if not previously utilized.

12

Global Green, Inc.

(A Development Stage Company)

Notes to the Consolidated Financial Statements

September 30, 2014

(unaudited)

NOTE 6EQUITY

In April 2010, the Company authorized the issuance of up to 100,000,000 shares of Preferred Stock at no par value.  As of September 30, 2014 and December 31, 2013, no shares are issued or outstanding.

In May 2010, the Company had a 10-to-1 stock forward split, changing its par value from $.0001 per share to $.00001 per share.  Right after the said stock split, the Company issued 20,000,000 shares of its common stock to certain shareholders for services rendered valued at $200.  This is recorded as a non-cash expense in the accompanying statement of operations.

In November 2010 the Company issued approximately 683 million shares of common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned issuance, the Company has become a majority-owned subsidiary of NHIL.

On March 21, 2011, the Company completed a private placement of common stock to accredited investors and raised $286,000 of working capital.

NOTE 7RELATED PARTY TRANSACTIONS AND COMMITMENTS

In January 2013, the Company entered into a convertible advance with the Company's Chief Executive Officer and Chairman. The convertible advance, with a face value of $300,000, bears interest at 5% per annum and is payable on demand. The convertible advance is convertible, at the holder's option, into the Company's common or preferred shares based on the value of the shares at the execution date of the advance.  The convertible advance is valued at the greater of the face value of the advance or the fair value of the shares, if converted.  At September 30, 2014 and December 31, 2013, the convertible advance, was recorded at $195,000 and $235,000, respectively.   Accrued interest related to this advance was $18,029 and $12,987 at September 30, 2014 and December 31, 2013, respectively, and is included in accounts payable and accrued expenses on the balance sheet.

Through its wholly-owned subsidiary, GGII, the Company has exclusive rights to the Licensing Agreement with NHIL, the Company's majority shareholder.  In accordance with this agreement, GGII assumes the financial responsibility for the acquisition and maintenance of all patents, as well as USDA's approval of the Vaccine.

NOTE 8CONTINGENCIES

During the normal course of business, the Company may be exposed to litigation.  When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies.  The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome.  If the Company determines than an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.  As of September 30, 2014, the Company is not aware of any contingent liabilities that should be reflected in the accompanying financial statements.

13

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our unaudited financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission.  Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking  statements are necessarily based upon estimates and assumptions that are inherently  subject to significant  business,  economic and competitive uncertainties and  contingencies,  many of which are beyond our control and many of which,  with  respect to future  business  decisions,  are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf.  We disclaim any obligation to update forward-looking statements.

The independent registered public accounting firm's report on the Company's financial statements as of December 31, 2013, and for each of the years in the two-year period then ended, includes a "going concern" explanatory paragraph, that describes substantial doubt about the Company's ability to continue as a going concern.

PLAN OF OPERATIONS

We had no operations prior to January 2009 and we did not have any revenues during the quarter ended September 30, 2014 nor the fiscal years ended December 31, 2013 and 2012. We have minimal capital, minimal cash, and only our intangible assets consist of our patents and patent applications, business plan, relationships and contacts. We are illiquid and need cash infusions from investors or shareholders to provide capital, or loans from any sources.

In March 2012, the Company completed its Final Efficacy Testing and  sent the results to the USDA.

In August 2012, the Company began a study to determine how long a chicken can be protected against Salmonella after it begins laying eggs. We believe that if a layer hen is not infected with the Salmonella bacteria or shows reduced levels of the bacteria, then neither the egg, nor the chick, when it hatches, will have Salmonella or the egg or chick will show reduced levels of the bacteria. We believe there is a "timelined" vaccine effect that will be logged and sequenced during the study, beginning from a newly-hatched chicken, to the 18-20 weeks before the chicken becomes a layer hen, and, after that, until the end of the hen's productive life. At the time of this filing, the protocols have been finished and we are in the process of identifying  manufacturers.  At the time of this filing, we have not been able to identify a manufacturer but are continuing to seek one.

In September 2013, the Company announced the signing of an agreement with Merial Ltd., the Animal Health Division of Sanofi, to conduct an internal evaluation of the Company's patented Salmogenics vaccine technology.  At the time of this filing, the Merial's internal evaluation has expired and the agreement with Merial expired on October 1, 2014.

In January 2013, the Company entered into a convertible advance with the Company's Chief Executive Officer and Chairman, Dr. Ghazvini. The convertible advance with a face value of $300,000, bears interest at 5% per annum and is payable on demand. The convertible advance is convertible, at the holder's option, into the Company's common or preferred shares based on the value of the shares at the execution date of the advance. During the nine months ended September 30, 2014, the Company made a $40,000 cash payment on the advance.

14

At September 30, 2014 and December 31, 2013, the convertible advance was recorded at $195,000 and $235,000, respectively.  Accrued interest related to this advance was $18,029 and $12,987 at September 30, 2014 and December 31, 2013, respectively, and is included in accounts payable and accrued expenses on the balance sheet.

At this time and for the next six months, the Company is looking and negotiating with other partners and vaccine manufacturers in order to initiate the designs of protocols for commercial production, their finalization and testing and continue to identify sources of financing. Management estimates an additional 18-24 month or longer delays for the USDA approval. Presently, the Company is arranging with a specific vaccine manufacturer for evaluation and completion of the studies.  

We will need substantial additional capital to support our proposed future operations.  We have no revenues, we will be unable to realize revenues until we have achieved USDA final approval.  We have no committed source for any funds as of date hereof.  No representation is made that any funds will be available when needed.  In the event funds cannot be raised when needed, we may not be able to carry out our business plan, may never achieve sales, and could fail in business as a result of these uncertainties.

RESULTS OF OPERATIONS

For the Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013

During the three months ended September 30, 2014 and 2013, the Company did not recognize any revenues from it operational activities.  Management does not anticipate recognizing any revenues from the sale of the Salmogenic vaccine, until the final approval of the USDA has been granted and that time the Company will be able to begin sales and marketing efforts.

During the three months ended September 30, 2014, the Company incurred operational expenses of $13,102.  During the three months ended September 30, 2013, the Company incurred operational expenses of $40,344.  The decrease of $27,242 was primarily a result of a $10,454 decrease in professional fees expenses and a $18,933 decrease in general and administrative expenses combined with a $3,000 increase in investor relations.

During the three months ended September 30, 2014, the Company recognized a net loss of $13,102 compared to a net loss of 40,344 during the three months ended September 30, 2013.  The decrease of $27,242 was a direct result of the expenses discussed above.

For the Nine  Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013

During the nine months ended September 30, 2014 and 2013, the Company did not recognize any revenues from it operational activities.  Management does not anticipate recognizing any revenues from the sale of the Salmogenic vaccine, until the final approval of the USDA has been granted and that time the Company will be able to begin sales and marketing efforts.

During the nine months ended September 30, 2014, the Company incurred operational expenses of $52,484.  During the nine months ended September 30, 2013, the Company incurred operational expenses of $91,830.  The decrease of $39,346 was primarily a result of a $38,520 decrease in general and administrative expenses combined with a $12,585 decrease in professional fees offset by a $9,000 increase in investor relations and a $5,000 increase in vaccine testing.  The increase in vaccine and testing expenses was a result of the Company's efforts regarding the vaccine, but also its focus on increasing public awareness of the Company.

During the nine months ended September 30, 2014, the Company recognized a net loss of $52,484 compared to a net loss of $91,830 during the nine months ended September 30, 2013.  The decrease of $39,346 was a direct result of the expenses discussed above.

15

LIQUIDITY

The independent registered public accounting firm's report on the Company's financial statements as of December 31, 2013, and for each of the years in the two-year period then ended, includes a "going concern" explanatory paragraph, that describes substantial doubt about the Company's ability to continue as a going concern.

At September 30, 2014, the Company had total current assets of $29,181, consisting of $27,181 in cash and  $2,000 travel advances to officers.  At September 30, 2014, total current liabilities were $222,559, consisting of $27,059 in accounts payable and accrued expenses, $500 due to shareholders, and a Convertible advance to related party of $195,000.  At September 30, 2014, the Company had working capital deficit of $193,378.

During the nine months ended September 30, 2014, the Company used $46,351 in funds in it operational activities.  During the nine months ended September 30, 2014, the Company recognized a net loss of $52,484 which was adjusted for $252 in amortization expense.  During the nine months ended September 30, 2013, the Company used $95,627 in its operations, a net loss of $91,830 was adjusted for the non-cash item of $252 in amortization expense.

During the nine months ended September 30, 2014, the Company used $40,000 in its financing activities, making a payment on the outstanding convertible advance made by its Chief Executive Officer and Chairman, discussed below.

On January 15, 2013 the Company entered into a revolving convertible advance with the Company's Chief Executive Officer and Chairman. The convertible advance, with a face value of $300,000, bears interest at 5% per annum and matures on March 31, 2015. The convertible advance is convertible, at the holder's option, into the Company's common or preferred shares based on the value of the shares at the execution date of the advance.  The convertible advance is valued at the greater of the face value of the advance or the fair value of the shares, if converted.  At September 30, 2014 and December 31, 2013, the convertible advance was recorded at $195,000 and $235,000, respectively.  Accrued interest related to this advance was $18,029 and $12,987 at September 30, 2014 and December 31, 2013, respectively, and is included in accounts payable and accrued expenses on the balance sheet.

Short Term

On a short-term basis, the Company has not generated any revenue or revenues sufficient to cover operations.  For short term needs the Company will be dependent on receipt, if any, of offering proceeds.

Capital Resources

The Company has only common stock as its capital resource.

The Company has no material commitments for capital expenditures within the next year, however if operations are commenced, substantial capital will be needed to pay for participation, investigation, exploration, acquisition and working capital.

Need for Additional Financing

The Company does not have capital sufficient to meet its cash needs.  The Company will have to seek loans or equity placements to cover such cash needs.  Once manufacturing and sales efforts commence, its needs for additional financing is likely to increase substantially.

No commitments to provide additional funds have been made by the Company's management or other stockholders.  Accordingly, there can be no assurance that any additional funds will be available to the Company to allow it to cover the Company's expenses as they may be incurred.

16

Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2014.

Earnings Per Share

The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2014 or September 30, 2013.

ITEM 3.  QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosures Controls and Procedures

We have adopted and maintain disclosure controls and procedures (as such term is defined in Rules  13a 15(e) and 15d-15(e)  under the Securities  Exchange Act of 1934,  as  amended  (the  "Exchange  Act")) and   that are  designed  to ensure  that information  required to be disclosed in our reports  under the Exchange Act, is recorded,  processed,  summarized and reported within the time periods  required under  the  SEC's  rules and forms  and that the  information  is  gathered  and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow for timely decisions regarding required disclosure.

As required by SEC Rule 15d-15(b), our Chief Executive/Financial Officer carried out an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 15d-14 as of the end of the period covered by this  report.  Based on the foregoing evaluation,  our Chief Executive Officer has concluded that our disclosure controls and procedures  are  effective  in  timely  alerting  them to  material  information required  to be  included  in  our  periodic  SEC  filings  and to  ensure  that information  required to be disclosed in our periodic SEC filings is accumulated and communicated to our management,  including our Chief Executive  Officer,  to allow  timely  decisions  regarding  required  disclosure.

There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2014, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

17

PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

None.

ITEM 1A.  RISK FACTORS

Not Applicable to Smaller Reporting Companies.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the period of July 1, 2014 through September 30, 2014, the Company did not make any issuances of its equity securities.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.  MINE SAFETY DISCLOSURE

Not Applicable.

ITEM 5.  OTHER INFORMATION

None.

18

ITEM 6.  EXHIBITS

Exhibits.  The following is a complete list of exhibits filed as part of this Form 10-Q.  Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

Exhibit 31.1 Certification of Chief Executive and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act

Exhibit 32.1 Certification of Principal Executive and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

Exhibit 101.INSXBRL Instance Document

Exhibit 101.SCHXBRL Taxonomy Extension Schema Document (1)

Exhibit 101.CALXBRL Taxonomy Extension Calculation Linkbase Document (1)

Exhibit 101.DEFXBRL Taxonomy Extension Definition Linkbase Document (1)

Exhibit 101.LABXBRL Taxonomy Extension Label Linkbase Document (1)

Exhibit 101.PREXBRL Taxonomy Extension Presentation Linkbase Document (1)

(1) Pursuant to Rule 406T of Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

19

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GLOBAL GREEN, INC.

(Registrant)

 

Dated:  November 14, 2014	By:	/s/ Dr. Mehran P. Ghazvini, DC
	Dr.  Mehran P. Ghazvini, DC
	(Principal Executive Officer, Chief Financial Officer and Principal Accounting  Officer)

20

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PERIODIC REPORT

I, Dr.  Mehran P. Ghazvini, DC, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Global Green, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. As the registrant's sole certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under  our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is  made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's 4th quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. As the registrant's certifying officer, I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 Date: November 14, 2014

/s/ Dr. Mehran P. Ghazvini, DC

Dr. Mehran P. Ghazvini, DC

(Principal Executive Officer and Chief Financial Officer, Principal Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF DISCLOSURE PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Global Green, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report") I, Dr.  Mehran P. Ghazvini, DC, Principal Executive Officer, Chief Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2014

/s/ Dr. Mehran P. Ghazvini, DC

 --------------------------------------------------------------------------------

Dr. Mehran P. Ghazvini, DC, (Principal Executive Officer,

Chief Financial Officer and Principal Accounting Officer)

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

XML

GOING CONCERN

9 Months Ended

Sep. 30, 2014

Going Concern [Abstract]

GOING CONCERN

NOTE 2 GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.  As of September 30, 2014, the Company has incurred net losses of $480,866 since inception (July 12, 2004).

Management's plans include raising capital through the equity markets to fund operations and eventually, the generating of revenue through its business; however, there can be no assurance that the Company will be successful in such activities.  These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

XML

RELATED PARTY TRANSACTIONS AND COMMITMENTS (Detail Textuals) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Jan. 31, 2013
Related Party Transaction [Line Items]
Convertible advance - related party	$ 195,000	$ 235,000
Chief Executive Officer And Chairman | Revolving convertible advance
Related Party Transaction [Line Items]
Convertible advance, face value			300,000
Convertible advance, interest rate per annum			5.00%
Convertible advance - related party	195,000	235,000
Chief Executive Officer And Chairman | Revolving convertible advance | Accounts payable and accrued expenses
Related Party Transaction [Line Items]
Accrued interest	$ 18,029	$ 12,987

XML

EQUITY (Detail Textuals) (USD $)	1 Months Ended		12 Months Ended	123 Months Ended			1 Months Ended
	Mar. 21, 2011	May 31, 2010	Dec. 31, 2010	Sep. 30, 2014	Dec. 31, 2013	Apr. 30, 2010	Nov. 29, 2010 Share Exchange Agreement Nutritional Health Institute, LLC ("NHIL")
Stockholders' Equity Note [Abstract]
Preferred stock, shares authorized				100,000,000	100,000,000	100,000,000
Preferred stock, no par value (in dollars per share)
Preferred stock, shares issued
Preferred stock, shares outstanding
Forward stock split ratio		10-to-1	10 to 1
Common stock, par value (in dollars per share)		$ 0.0001		$ 0.00001	$ 0.00001
Number of common shares issued for services rendered		20,000,000
Value of common shares issued for services rendered		$ 200
Proceeds from share issuance through private placement	$ 286,000			$ 286,000
Stockholders Equity Note [Line Items]
Common stock shares issued under acquisition							683,000,000
Percentage of ownership of the Company							93.00%

XML

NATURE OF ORGANIZATION

9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF ORGANIZATION

NOTE 1 NATURE OF ORGANIZATION

Global Green, Inc. (the "Company") is a Florida Corporation incorporated on July 12, 2004 as a wholly owned subsidiary of Global Assets & Services, Inc.  In September 2004, the Company was spun out into a separate legal entity.  The Company changed its name from The Global Tech Assets, Inc. to Global Green, Inc. in April 2010 and its fiscal period end is December 31.

The Company is in the development stage.  The principal activities during the development stage include organizing the corporate structure, implementing the Company's business plan and raising capital.  Although the Company was formed in 2004, it did not have any operating activities until 2010.

Under the Share Exchange Agreement executed on November 29, 2010, between the Company and Nutritional Health Institute, LLC ("NHIL"), the Company acquired 100% of the issued and outstanding stock of Global Green International, Inc. ("GGII"), a wholly owned subsidiary of NHIL. At the same time, the Company issued approximately 683 million shares of its common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned acquisition as per the Share Exchange Agreement, the Company has become a majority-owned subsidiary of NHIL. As the effective control over GGII did not change, in accordance with Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") 805 Business Combinations, GGII is consolidated at its book value (See Note 4).  Prior to November 2010, GGII had no assets or operations, so there is no impact to the historical financial statements.

GGII, a wholly-owned subsidiary of the Company, has been granted the exclusive worldwide rights (the "Licensing Agreement") to manufacture, distribute, market and sell a Salmonella Antigen and Vaccine (the "Vaccine").  The Licensing Agreement was executed between NHIL and GGII before the Company acquired the 100% ownership of GGII and is the only asset of GGII.

In February 2011, the Vaccine has been entered into the final phase of becoming a United States Department of Agriculture ("USDA") approved vaccine for the in ovo vaccination of chicken eggs to provide immunity against Salmonella bacteria. In May 2011, the United States Patent and Trademark Office granted a patent for the method and composition in the Vaccine. In August 2011, an additional patent was granted related to the vaccine.

XML

Consolidated Balance Sheets (unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 27,181	$ 113,532
Travel advances to officer	2,000	6,000
Prepaid expenses		750
Total current assets	29,181	120,282
Intangible asset, net	5,543	5,795
Total assets	34,724	126,077
Current liabilities:
Accounts payable and accrued expenses	27,059	25,928
Due to shareholders	500	500
Convertible advance- related party (see Note 7)	195,000	235,000
Total liabilities	222,559	261,428
Shareholders' deficit:
Preferred stock; no par value; 100,000,000 shares authorized; no shares outstanding at September 30, 2014 or December 31, 2013
Common stock; $.00001 par value; 3,000,000,000 shares authorized; 745,761,432 shares issued and outstanding at September 30, 2014 or December 31, 2013	7,458	7,458
Additional paid in capital	285,573	285,573
Deficit accumulated during the development stage	(480,866)	(428,382)
Total shareholders' deficit	(187,835)	(135,351)
Total liabilities and shareholders' deficit	$ 34,724	$ 126,077

XML

Consolidated Statement of Shareholders' Deficit (unaudited) (Parentheticals)	1 Months Ended	12 Months Ended
	May 31, 2010	Dec. 31, 2010
Statement Of Stockholders Equity [Abstract]
Forward stock split ratio	10-to-1	10 to 1

XML

INTANGIBLE ASSET (Detail Textuals) (Share Exchange Agreement, Nutritional Health Institute, LLC ("NHIL"), Global Green International Inc.)	Nov. 29, 2010
Share Exchange Agreement | Nutritional Health Institute, LLC ("NHIL") | Global Green International Inc.
Finite-Lived Intangible Assets [Line Items]
Percentage of issued and outstanding stock acquired	100.00%

XML

TAXES - Components of income tax expense (Details) (USD $)	9 Months Ended		123 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current tax benefit	$ (19,734)	$ (34,528)	$ (137,208)
Change in valuation allowance	19,734	34,296	137,208
Income tax expense

XML

Consolidated Statement of Cash Flows (unaudited) (USD $)	9 Months Ended		123 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (52,484)	$ (91,830)	$ (480,866)
Adjustments to reconcile net loss to net cash from operating activities:
Amortization	252	252	1,288
Stock based compensation			200
Change in assets and liabilities:
Travel advances to officer	4,000		(2,000)
Prepaid expenses	750	375
Accounts payable and accrued expenses	1,131	(2,424)	27,059
Due from shareholders		(2,000)
Due to shareholders			500
Net cash from operating activities	(46,351)	(95,627)	(453,819)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from share issuance			286,000
Proceeds from convertible advance - related party		300,000	300,000
Repayments on convertible advance - related party	(40,000)	(37,000)	(105,000)
Net cash from financing activities	(40,000)	263,000	481,000
NET CHANGE IN CASH	(86,351)	167,373	27,181
CASH, beginning of period	113,532	4,027
CASH, end of period	27,181	171,400	27,181
SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES:
Common stock issued for acquisition of Global Green International, Inc.			$ 6,831

XML

Consolidated Balance Sheets (unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	745,761,432	745,761,432
Common stock, shares outstanding	745,761,432	745,761,432

XML

INTANGIBLE ASSET (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of components of intangible assets

	September 30, 2014			December 31, 2013
License agreement	$	6,831		$	6,831
Accumulated amortization		(1,288	)		(1,036	)
	$	5,543		$	5,795

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 10, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	GLOBAL GREEN INC.
Entity Central Index Key	0001522724
Trading Symbol	gogc
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		745,761,432
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

XML

TAXES (Tables)

9 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Schedule of components of income tax expense

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Current tax benefit	$	(19,734	)	$	(34,528	)	$	(137,208	)
Change in valuation allowance		19,734			34,528			137,208
	$	-		$	-		$	-

Schedule of difference between income tax expense computed by applying the statutory federal income tax rate

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Pretax loss at federal statutory rate	$	(17,845	)	$	(31,012	)	$	(124,072	)
State income benefit, net of federal benefit		(1,889	)		(3,284	)		(13,136	)
Change in valuation allowance		19,734			34,296			137,208
	$	-		$	-		$	-

Schedule of components of deferred taxes

	September 30, 2014			December 31, 2013
Deferred income tax assets:
Operating loss carryforwards	$	137,208		$	161,073
Less: Valuation allowance		(137,208	)		(161,073	)
Net deferred tax asset	$	-		$	-

XML

Consolidated Statement of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended		123 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Professional fees	5,040	15,494	17,931	30,516	178,099
Testing for U.S. Department of Agriculture's approval					137,800
General and administrative	1,940	20,873	10,013	48,533	84,612
Investor relations	3,000		9,000		32,231
Interest expense (see Note 7)	2,438	3,408	8,038	10,908	21,025
Consulting fees					10,200
Stock transfer agent fees	600	485	2,250	1,570	10,422
Vaccine testing			5,000		5,000
Amortization	84	84	252	252	1,288
Bank fees				51	189
Total operating expenses	13,102	40,344	52,484	91,830	480,866
NET LOSS	$ (13,102)	$ (40,344)	$ (52,484)	$ (91,830)	$ (480,866)
Net loss per share applicable to common stockholders - basic and diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average number of shares outstanding - basic and diluted	745,761,432	745,761,432	745,761,432	745,761,432

XML

TAXES

9 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

TAXES

NOTE 5TAXES

The components of income tax expense for the periods ended are as follows:

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Current tax benefit	$	(19,734	)	$	(34,528	)	$	(137,208	)
Change in valuation allowance		19,734			34,528			137,208
	$	-		$	-		$	-

The difference between income tax expense computed by applying the statutory federal income tax rate to earnings before taxes for the periods ended are as follows:

	September 30, 2014			September 30, 2013			Inception to September 30, 2014
Pretax loss at federal statutory rate	$	(17,845	)	$	(31,012	)	$	(124,072	)
State income benefit, net of federal benefit		(1,889	)		(3,284	)		(13,136	)
Change in valuation allowance		19,734			34,296			137,208
	$	-		$	-		$	-

The components of deferred taxes are as follows:

	September 30, 2014			December 31, 2013
Deferred income tax assets:
Operating loss carryforwards	$	137,208		$	161,073
Less: Valuation allowance		(137,208	)		(161,073	)
Net deferred tax asset	$	-		$	-

At September 30, 2014 and December 31, 2013, a valuation allowance was established for the entire amount of the net deferred tax asset as the realization of the deferred tax asset is dependent on future taxable income.

At September 30, 2014, the Company had net operating loss carryforwards for tax purposes of $480,866, which will expire beginning in 2031, if not previously utilized.

XML

INTANGIBLE ASSET

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSET

NOTE 4INTANGIBLE ASSET

The Company accounts for its intangible asset in accordance FASB ASC 350 Intangibles—Goodwill and Other.  The intangible assets consist of the Licensing Agreement and is carried at an allocated cost, less accumulated amortization.  The Licensing Agreement was executed on November 29, 2010 between NHIL and GGII, before the Company acquired the 100% ownership of GGII as described in Note 1. The provisions in the License Agreement include the Company's responsibilities to protect the Vaccine information and to assume financial responsibilities for the acquisition of USDA approval of the Vaccine.  The License Agreement has no expiration date, but is being amortized over the 20 year legal life of the related patent. As the effective control over GGII did not change after acquisition by the Company, in accordance with FASB ASC 805, Business Combinations, the License Agreement is consolidated at the book value.

Components of intangible assets at the periods ended are as follows:

	September 30, 2014			December 31, 2013
License agreement	$	6,831		$	6,831
Accumulated amortization		(1,288	)		(1,036	)
	$	5,543		$	5,795

XML

INTANGIBLE ASSET (Detail Textuals 1) (Licensing Agreement)	1 Months Ended
	Nov. 29, 2010
Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Useful life of the patent	20 years

XML

NATURE OF ORGANIZATION (Detail Textuals) (Share Exchange Agreement, Nutritional Health Institute, LLC ("NHIL")) In Millions, unless otherwise specified	1 Months Ended
	Nov. 29, 2010
Nature Of Organization [Line Items]
Common stock shares issued under acquisition	683
Percentage of ownership of the Company	93.00%
Global Green International Inc.
Nature Of Organization [Line Items]
Percentage of issued and outstanding stock acquired	100.00%

XML

CONTINGENCIES

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES

NOTE 8CONTINGENCIES

During the normal course of business, the Company may be exposed to litigation.  When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies.  The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome.  If the Company determines than an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.  As of September 30, 2014, the Company is not aware of any contingent liabilities that should be reflected in the accompanying financial statements.

XML

EQUITY

9 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

EQUITY

NOTE 6EQUITY

In April 2010, the Company authorized the issuance of up to 100,000,000 shares of Preferred Stock at no par value.  As of September 30, 2014 and December 31, 2013, no shares are issued or outstanding.

In May 2010, the Company had a 10-to-1 stock forward split, changing its par value from $.0001 per share to $.00001 per share.  Right after the said stock split, the Company issued 20,000,000 shares of its common stock to certain shareholders for services rendered valued at $200.  This is recorded as a non-cash expense in the accompanying statement of operations.

In November 2010 the Company issued approximately 683 million shares of common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned issuance, the Company has become a majority-owned subsidiary of NHIL.

On March 21, 2011, the Company completed a private placement of common stock to accredited investors and raised $286,000 of working capital.

XML

RELATED PARTY TRANSACTIONS AND COMMITMENTS

9 Months Ended

Sep. 30, 2014

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS AND COMMITMENTS

NOTE 7RELATED PARTY TRANSACTIONS AND COMMITMENTS

In January 2013, the Company entered into a convertible advance with the Company's Chief Executive Officer and Chairman. The convertible advance, with a face value of $300,000, bears interest at 5% per annum and is payable on demand. The convertible advance is convertible, at the holder's option, into the Company's common or preferred shares based on the value of the shares at the execution date of the advance.  The convertible advance is valued at the greater of the face value of the advance or the fair value of the shares, if converted.  At September 30, 2014 and December 31, 2013, the convertible advance, was recorded at $195,000 and $235,000, respectively.   Accrued interest related to this advance was $18,029 and $12,987 at September 30, 2014 and December 31, 2013, respectively, and is included in accounts payable and accrued expenses on the balance sheet.

Through its wholly-owned subsidiary, GGII, the Company has exclusive rights to the Licensing Agreement with NHIL, the Company's majority shareholder.  In accordance with this agreement, GGII assumes the financial responsibility for the acquisition and maintenance of all patents, as well as USDA's approval of the Vaccine.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") on the accrual basis of accounting.  All significant intercompany accounts and transactions have been eliminated in consolidation.  The interim financial statements reflect all adjustments, which are, in the opinion of management, necessary in order to make the financial statements not misleading.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the financial statements.  The significant accounting policies, estimates and related judgments underlying the Company's financial statements are summarized below.  In applying these policies, management makes subjective judgments that frequently require estimates about matters that are inherently uncertain.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents.  There were no cash equivalents at September 30, 2014 and December 31, 2013.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2014.

Earnings Per Share

Earnings Per Share

The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2014 and December 31, 2013.

Concentrations

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash.

Occasionally, cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation ("FDIC").  Accordingly, the Company places its cash and cash equivalents with financial institutions considered by management to be of high credit quality.  At times, the Company's cash balances may be in excess of the FDIC limits.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company adopted Statement of Financial Accounting Standards ("SFAS") No. 157 Fair Value Measurements ("SFAS 157"), superseded by ASC 820-10, which defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. The impact of adopting ASC 820-10 was not significant to the Company's financial statements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.  Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.  The valuation of our derivative liability is determined using Level 1 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014 and December 31, 2013.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.  These financial instruments include cash, accounts payable, accrued expenses and advance.

Income Taxes

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies. 

The Company files income tax returns in the United States and Florida, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company's federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with FASB ASC 740, Income Taxes, and has not identified any significant tax positions, other than those disclosed.

Subsequent Events

Subsequent Events

In accordance with FASB ASC 855, Subsequent Events, the Company evaluated subsequent events through November 10, 2014, the date the financial statements were available for issue.

XML

INTANGIBLE ASSET - Components of intangible assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
License agreement	$ 6,831	$ 6,831
Accumulated amortization	(1,288)	(1,036)
Intangible asset, net	$ 5,543	$ 5,795

XML

TAXES - Components of deferred taxes (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Deferred income tax assets:
Operating loss carryforwards	$ 137,208	$ 161,073
Less: Valuation allowance	(137,208)	(161,073)
Net deferred tax asset

XML

Consolidated Statement of Shareholders' Deficit (unaudited) (USD $)	Common Stock	Additional Paid in Capital	Accumulated During the Development Stage	Total
Balance at Jul. 12, 2004
Balance (shares) at Jul. 12, 2004
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance	314	(314)
Share issuance (in shares)	3,141,597
Balance at Dec. 31, 2004	314	(314)
Balance (shares) at Dec. 31, 2004	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance
Balance at Dec. 31, 2005	314	(314)
Balance (shares) at Dec. 31, 2005	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance
Balance at Dec. 31, 2006	314	(314)
Balance (shares) at Dec. 31, 2006	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance
Balance at Dec. 31, 2007	314	(314)
Balance (shares) at Dec. 31, 2007	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance
Balance at Dec. 31, 2008	314	(314)
Balance (shares) at Dec. 31, 2008	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance
Balance at Dec. 31, 2009	314	(314)
Balance (shares) at Dec. 31, 2009	3,141,597
Increase Decrease In Stockholders Equity [Roll Forward]
Recapitalization due to 10 to 1 stock split (in shares)	28,274,370
Stock based compensation	200			200
Stock based compensation (in shares)	20,000,000
Share issuance	6,831			6,831
Share issuance (in shares)	683,097,847
Net loss			(5,728)	(5,728)
Balance at Dec. 31, 2010	7,345	(314)	(5,728)	1,303
Balance (shares) at Dec. 31, 2010	734,513,814
Increase Decrease In Stockholders Equity [Roll Forward]
Share issuance	113	285,887		286,000
Share issuance (in shares)	11,247,618
Net loss			(191,800)	(191,800)
Balance at Dec. 31, 2011	7,458	285,573	(197,528)	95,503
Balance (shares) at Dec. 31, 2011	745,761,432
Increase Decrease In Stockholders Equity [Roll Forward]
Net loss			(114,900)	(114,900)
Balance at Dec. 31, 2012	7,458	285,573	(312,428)	(19,397)
Balance (shares) at Dec. 31, 2012	745,761,432
Increase Decrease In Stockholders Equity [Roll Forward]
Net loss			(115,954)	(115,954)
Balance at Dec. 31, 2013	7,458	285,573	(428,382)	(135,351)
Balance (shares) at Dec. 31, 2013	745,761,432			745,761,432
Increase Decrease In Stockholders Equity [Roll Forward]
Net loss			(52,484)	(52,484)
Balance at Sep. 30, 2014	$ 7,458	$ 285,573	$ (480,866)	$ (187,835)
Balance (shares) at Sep. 30, 2014	745,761,432			745,761,432

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") on the accrual basis of accounting.  All significant intercompany accounts and transactions have been eliminated in consolidation.  The interim financial statements reflect all adjustments, which are, in the opinion of management, necessary in order to make the financial statements not misleading.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the financial statements.  The significant accounting policies, estimates and related judgments underlying the Company's financial statements are summarized below.  In applying these policies, management makes subjective judgments that frequently require estimates about matters that are inherently uncertain.

Cash and Cash Equivalents

The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents.  There were no cash equivalents at September 30, 2014 and December 31, 2013.

Revenue Recognition

The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2014.

Earnings Per Share

The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2014 and December 31, 2013.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash.

Occasionally, cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation ("FDIC").  Accordingly, the Company places its cash and cash equivalents with financial institutions considered by management to be of high credit quality.  At times, the Company's cash balances may be in excess of the FDIC limits.

Fair Value of Financial Instruments

The Company adopted Statement of Financial Accounting Standards ("SFAS") No. 157 Fair Value Measurements ("SFAS 157"), superseded by ASC 820-10, which defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. The impact of adopting ASC 820-10 was not significant to the Company's financial statements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.  Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.  The valuation of our derivative liability is determined using Level 1 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014 and December 31, 2013.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.  These financial instruments include cash, accounts payable, accrued expenses and advance.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.

The Company files income tax returns in the United States and Florida, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company's federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with FASB ASC 740, Income Taxes, and has not identified any significant tax positions, other than those disclosed.
 

Subsequent Events

In accordance with FASB ASC 855, Subsequent Events, the Company evaluated subsequent events through November 10, 2014, the date the financial statements were available for issue.

XML

TAXES (Detail Textuals) (USD $)	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 480,866

XML

GOING CONCERN (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended				123 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2014
Going Concern [Abstract]
Net losses	$ (13,102)	$ (40,344)	$ (52,484)	$ (91,830)	$ (115,954)	$ (114,900)	$ (191,800)	$ (5,728)	$ (480,866)